Mountain Valley MD Holdings Inc (CSE:MVMD, OTCQB:MVMDF) has welcomed the publication of a peer-reviewed study on its patented Soluvec formulation in the journal Therapeutic Delivery.
The study highlighted the benefits of Soluvec, a solvent-free aqueous Ivermectin invention, and confirmed that parenteral administration of Soluvec led to an Ivermectin drug exposure of approximately seven times higher than traditional oral drug dosing, with greater bioavailability, offering the potential for enhanced therapeutic effectiveness.
The study also showed an increased duration of exposure, with higher peak levels. It also suggested that the enhanced bioavailability of Ivermectin in Soluvec may allow a lower dose to achieve the desired therapeutic effects.
The study underscored Soluvec’s favourable safety profile, with minimal side effects observed.
“The results point to the possibility of easier treatment regimens and improved therapeutic outcomes not just for livestock but potentially for humans as well,” the company added.
“The peer-review process for consideration of publication of MVMD’s study is a third-party validation of our science and the potential commercial efficacy of our Soluvec product,” Dennis Hancock, president and CEO of Mountain Valley MD said in a statement.
The article 'Physical and Pharmacokinetic Characterization of Soluvec, a novel, solvent-free aqueous Ivermectin formulation' can be accessed here.